お知らせ

2017/11/06

リバーロキサバンの冠状動脈疾患および末梢動脈疾患への効能追加を欧州で申請

Bayer submits application for marketing approval of rivaroxaban for patients with coronary or peripheral artery disease to European Medicines Agency
November 6, 2017
BayerFactpr Xa inhibitor,